Here are the 10-K annual reports from Telomir Pharmaceuticals, Inc. (TELO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow TELO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TELO filings page.
Telomir Pharmaceuticals, Inc. files its annual report for the year ended December 31, 2025, describing a preclinical-stage biotech focused on Telomir-1, a small molecule targeting metal-ion dysregulation, oxidative stress, epigenetics, mitochondrial function, and telomere integrity to address aging and age-related diseases.
The company has no revenues, an accumulated deficit of $41.0 million as of December 31, 2025, and its auditors raise substantial doubt about its ability to continue as a going concern. Telomir plans to submit an IND for Telomir-1 in 2026 and then start a Phase 1/2 trial, subject to regulatory and funding constraints.
Telomir relies on a related-party license from MIRALOGX for U.S. rights to Telomir-1, paying an 8% royalty on net sales and certain milestone revenue, while foreign rights remain with MIRALOGX. A pending merger with TELI Pharmaceuticals, Inc. is expected to align worldwide Telomir-1 rights under one public company, with TELI shareholders receiving one Telomir share per TELI share.